Novel silver(I) compounds display strong activity towards resistant ovarian and colorectal cancer cell lines (original) (raw)

2021, Proceedings of 7th International Electronic Conference on Medicinal Chemistry

Carboplatin (CBP) is used to treat several types of cancers including ovarian carcinoma (OC). However, drug resistance is a frequent obstacle for successful treatment. In the quest for new (metallo)drugs to treat OC with acquired resistance, we have explored the use of silver(I)-based compounds containing 2,2'-bipyridine derivatives and triphenylphosphane (PPh 3) or 1,2-bis(diphenylphosphino)ethane (dppe) co-ligands as prospective anticancer agents. Their cytotoxic activity was tested in two human OC models (SKOV-3 and MESOV),

Sign up for access to the world's latest research.

checkGet notified about relevant papers

checkSave papers to use in your research

checkJoin the discussion with peers

checkTrack your impact